2024

1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

   Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

2. Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale

   Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 10, Núm. 2

3. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

   Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Vol. 30, Núm. 2, pp. 223-230

4. Childhood-Onset Non-Infectious Uveitis in the “Biologic Era”. Results From Spanish Multicenter Multidisciplinary Real-World Clinical Settings

   Ocular Immunology and Inflammation, Vol. 32, Núm. 9, pp. 2159-2169

5. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

   Multiple Sclerosis and Related Disorders, Vol. 90

6. Clinical-Hematological Changes and Predictors of Severity in Acute Food Protein–Induced Enterocolitis Syndrome Reactions at Oral Food Challenge: A Multicenter Observational Study

   Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 9, pp. 2454-2467.e8

7. Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis

   Patient Preference and Adherence , Vol. 18, pp. 1163-1171

8. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry

   Neuromuscular Disorders, Vol. 34, pp. 1-8

9. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

   Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

10. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER)

    Rheumatology International, Vol. 44, Núm. 11, pp. 2445-2455

11. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

12. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

13. Effectiveness and safety of levodopa–entacapone–carbidopa infusion in Parkinson disease: A real-world data study

    European Journal of Neurology

14. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

15. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

16. GEMA-Na and MELD 3.0 severity scores to address sex disparities for accessing liver transplantation: a nationwide retrospective cohort study

    eClinicalMedicine, Vol. 74

17. Genetic Characterization of Kidney Failure of Unknown Etiology in Spain: Findings From the GENSEN Study

    American Journal of Kidney Diseases

18. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

19. Glycemic control and prescription profiles in internal medicine inpatients: The role of frailty

    European Journal of Internal Medicine, Vol. 121, pp. 103-108

20. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199